The prevention or delay of type 2 diabetes: American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases

Diabetes Care

Volumn 25, Issue 4, 2002, Pages 742-749

  Sherwin, Robert S ^a   Anderson, Robert M ^a   Buse, John B ^a   Chin, Marshall H ^a   Eddy, David ^a   Fradkin, Judith ^a   Ganiats, Theodore G ^a   Ginsberg, Henry N ^a   Kahn, Richard ^a   Nwankwo, Robin ^a   Rewers, Marion ^a   Schlessinger, Leonard ^a   Stem, Michael ^a   Vinicor, Frank ^a   Zinman, Bernard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; MASS SCREENING; METHODOLOGY;

DIABETES MELLITUS, TYPE 2; HUMANS; MASS SCREENING;

EID: 0036550695     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.4.742     Document Type: Review

References (60)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
2. Reaven GM: Banting Lecture: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
3. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
4. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316:823-828, 1998
5. The DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
6. Eastman RC, Cowie CC, Harris MI: Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 20:127-128, 1997
7. Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 24:447-453, 2001
8. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 124 years. Diabetes Care 22:233-240, 1999
9. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367, 1998
10. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E: Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22:45-49, 1999
11. Harris MI: Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642-652, 1993
12. Wei M, Gaskill SP, Haffner SM, Stern MP: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care 21:1167-1172, 1998
13. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
14. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 287:867-870, 1983
15. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
16. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
17. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
18. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
19. Moss SE, Klein R, Klein BE, Meuer SM: The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473-2479, 1994
20. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk) BMJ 322:15-18, 2001
21. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
23. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012, 1999
24. Rajala U, Laakso M, Qiao Q, Keinanen-Kiukaanniemi S: Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes Care 21:1664-1669, 1998
25. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-819, 1992
26. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC: UKPDS: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116:297-303, 1998
27. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
28. Klein R, Klein BE, Moss SE: Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 16:1325-1330, 1993
29. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
30. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
31. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
32. Diabetes Prevention Research Group: Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med 346:393-403, 2002
33. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention in type 2 diabetes. Diabetes Care 22:623-634, 1999
34. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23: 1619-1629, 2000
35. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Prevention of type 2 diabetes: the role of pancreatic B-cell rest. (Submitted for publication)
36. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data: Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21:1720-1725, 1998
37. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laasko M, for the STOP-NIDDM Trial Research Group: Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomized clinical trial: the STOP-NIDDM Trial. Lancet. In press
38. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109-2113, 2001
39. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108-1112, 2000
40. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 22: 399-402, 1999
41. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701-710, 1997
42. Stern MP, Williams K, Haffner SM: Identification of individuals at high risk of type 2 diabetes: do we need the oral glucose tolerance test. Ann Intern Med. In press
43. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 15:1141-1155, 1992
44. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 282:1523-1529, 1999
45. U.S. Department of Health & Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996
46. Engelgau MM, Narayan KM, Herman WH: Screening for type 2 diabetes. Diabetes Care 23:1563-1580, 2000
47. CDC Diabetes Cost-Effectiveness Study Group: The cost-effectiveness of screening for type 2 diabetes. JAMA 280:1757-1763, 1998
48. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 20:1859-1862, 1997
49. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23:S5-S20, 2001
50. Stolk RP, Orchard TJ, Grobbee DE: Why use the oral glucose tolerance test? Diabetes Care 18:1045-1049, 1995
51. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298-305, 1996
52. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey 1988-1994. Diabetes Care 21:518-524, 1998
53. American Diabetes Association: Type 2 diabetes in children and adolescents. Diabetes Care 23:381-389, 2000
54. Troisi RJ, Cowie CC, Harris MI: Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 284:3157-3159, 2000
55. Wing RR, Goldstein MG, Acton KJ, Birch LL, Jakicic JM, Sallis JF Jr, Smith-West D, Jeffery RW, Surwit RS: Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 24:117-123, 2001
56. National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6 (Suppl. 2):51S-209S, 1998
57. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health: Physical activity and cardiovascular health. JAMA 276:241-246, 1996
58. The Writing Group for the Activity Counseling Trial Research Group: Effects of physical activity counseling in primary care: the Activity Counseling Trial: a randomized controlled trial. JAMA 286:677-687, 2001
59. Wee CC, McCarthy EP, Davis RB, Phillips RS: Physician counseling about exercise. JAMA 282:1583-1588, 1999
60. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000